SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-036563
Filing Date
2023-11-03
Accepted
2023-11-03 08:10:27
Documents
14
Period of Report
2023-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20231103.htm   iXBRL 8-K 30641
2 EX-99.1 ovid2023q3exhibit991.htm EX-99.1 71130
6 ovid-therapeutics_logo750s.jpg GRAPHIC 23227
  Complete submission text file 0001628280-23-036563.txt   273894

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20231103.xsd EX-101.SCH 1898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20231103_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20231103_pre.xml EX-101.PRE 13044
8 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20231103_htm.xml XML 2914
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 231374543
SIC: 2834 Pharmaceutical Preparations